华尔街投行Leerink Partners调整了对爱德华兹生命科学的评级,将该公司股票从“与大盘持平”上调至“跑赢大盘”。与此同时,分析师还将目标股价从原先的87美元提高至101美元。这一动作反映出机构对爱德华兹未来前景的乐观态度。
华尔街投行Leerink Partners调整了对爱德华兹生命科学的评级,将该公司股票从“与大盘持平”上调至“跑赢大盘”。与此同时,分析师还将目标股价从原先的87美元提高至101美元。这一动作反映出机构对爱德华兹未来前景的乐观态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.